$2.15
7.14% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US92859E1082
Symbol
VVOS

Vivos Therapeutics Inc Stock price

$2.15
-0.06 2.50% 1M
-0.75 25.78% 6M
-2.15 50.00% YTD
-0.10 4.24% 1Y
-33.36 93.96% 3Y
-222.61 99.05% 5Y
-222.61 99.05% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.17 7.14%
ISIN
US92859E1082
Symbol
VVOS
Sector
Industry

Key metrics

Market capitalization $12.63m
Enterprise Value $11.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.80
P/S ratio (TTM) P/S ratio 0.86
P/B ratio (TTM) P/B ratio 2.87
Revenue growth (TTM) Revenue growth 9.47%
Revenue (TTM) Revenue $14.63m
EBIT (operating result TTM) EBIT $-11.31m
Free Cash Flow (TTM) Free Cash Flow $-14.51m
Cash position $2.34m
EPS (TTM) EPS $-1.92
P/S forward 0.83
EV/Sales forward 0.76
Short interest 4.89%
Show more

Is Vivos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vivos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vivos Therapeutics Inc forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Vivos Therapeutics Inc forecast:

Buy
50%
Hold
50%

Financial data from Vivos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
15 15
10% 10%
100%
- Direct Costs 6.65 6.65
9% 9%
45%
7.98 7.98
10% 10%
55%
- Selling and Administrative Expenses 19 19
18% 18%
128%
- Research and Development Expense - -
-
-
-11 -11
31% 31%
-73%
- Depreciation and Amortization 0.61 0.61
3% 3%
4%
EBIT (Operating Income) EBIT -11 -11
30% 30%
-77%
Net Profit -11 -11
28% 28%
-77%

In millions USD.

Don't miss a Thing! We will send you all news about Vivos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vivos Therapeutics Inc Stock News

Neutral
Seeking Alpha
5 days ago
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.
Neutral
GlobeNewsWire
7 days ago
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate t...
Neutral
GlobeNewsWire
about one month ago
By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-in...
More Vivos Therapeutics Inc News

Company Profile

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Head office United States
CEO R. Huntsman
Employees 109
Founded 2016
Website www.vivos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today